American BioMed Reports On First Quarter 2000 Operating Improvements and Forward Momentum.

Business/Medical Editors

THE WOODLANDS, Texas--(BUSINESS WIRE)--May 12, 2000

--Conference Call to Be Held Tuesday, June 6th--

American BioMed, Inc. (OTC:BB:ABMI) today announced results for the first quarter ending March 31, 2000. Revenues of $64,921 represented a 116% sales increase from the fourth quarter of 1999. Under the Company's manufacturing agreement with MRI of Tucson, Arizona, costs of sales decreased 63%, from the first quarter of the prior year.

The Company achieved a gross profit margin of 27% for the quarter, or $17,603, in comparison to a 12% deficit during the first three months of 1999. After sales, general, and administrative expenses, research and development costs, and other corporate expenses, the quarterly net loss decreased 46%, from $581,145 in 1999 to $311,713 for 2000.

American BioMed's Chairman and Interim Chief Executive Officer, Justine B. Corday, commented, "Additional, sustained production gains are essential to relieve shipping backlogs and to increase customer confidence for order and reorder growth. However, these changes represent measurable progress in our commitment to transition the Company as rapidly as manageable from a development stage enterprise to a fully commercial company."

Separately, the Company reported it would hold a dial-in investor conference on Tuesday, June 6th at 4pm Eastern Time. The dial in number is 800-289-0437. There will be a 48 hour replay of the teleconference for those unable to participate. That dial in number is 888-203-1112 - confirmation code 563982. Ms. Corday stated, "Our stockholders have suggested that we offer additional opportunities for progress information and questions. The new management group, which assumed leadership in mid-March, supports such initiatives and welcomes the opportunity to hear from its investors." Additional dial-in information will be provided in a forthcoming announcement and on the Company's website at www.americanbiomed.com.

American BioMed, Inc. develops, manufactures, and markets devices for minimally-invasive cardiology and other surgical procedures.

This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. While based on assumptions the Company believes are reasonable, actual results could differ materially based on changes in these or unforeseen factors, and the Company assumes no obligation to publicly update or revise any forward looking statements herein. Among such uncertainties are government regulation; results of research, development, and clinical testing; general economic and other market conditions; pricing and reimbursement for medical care; and market competition. Please see the Company's Securities and Exchange Commission filings for detailed discussion of such risk factors.